Vitamin B3 and Improved Inner Retinal Function

Doses used in studies

g/day: 1.5–3 (median 2.25, IQR 1.5–3) — 1 study

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 1 study

1 of 1 paper

Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.

2020-07-28
RCT
Clinical & experimental ophthalmology 48(7)
- Flora Hui
- Jessica Tang
- Pete A Williams
- Myra B McGuinness
- Xavier Hadoux
- Robert J Casson
- Michael Coote
- Ian A Trounce
- Keith R Martin
- Peter van Wijngaarden
- Jonathan G Crowston

PubMed: 32721104
DOI: 10.1111/ceo.13818

2 Insights on

Improved Inner Retinal Function

High evidence
Highly Cited
Clinical

PhNR Vmax improved beyond 95% coefficient of repeatability in 23% of participants following nicotinamide vs 9% on placebo. Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (P = .02) on nicotinamide and 5.2% [-4.2%, 14.6%], (P = .27) on placebo. Vmax ratio improved by 12.6% [5.0%, 20.2%], (P = .002) following nicotinamide, 3.6% [-3.4%, 10.5%], (P = .30) on placebo.

Effect: Beneficial
Effect size: Moderate
Significant: Yes
Dose: 1.5 g/day then 6 weeks of 3.0 g/day